Stopping aspirin early after stent placement in people with acute coronary syndrome
Compares one blood-thinning drug with two in people after a heart stent.
Key facts
- Who runs it
- Gyeongsang National University Hospital
- Where
- Jinju, South KoreaSee the site
- Trial code
- Registry title
- Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 2,200 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 31 Jan 2033
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Early P2Y12 Inhibitor Monotherapy
- Standard Dual Antiplatelet Therapy
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute coronary syndrome who had a successful stent procedure guided by ultrasound inside the artery. It compares stopping aspirin early with standard two-drug treatment.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- Acute coronary syndrome: STEMI, NSTEMI or unstable angina. Complete revascularization after successful IVUS-guided PCI, with randomization within 96 hours after PCI.
- Earlier treatment
- Must have had a successful IVUS-guided PCI with a drug-eluting stent in the culprit lesion. Planned staged PCI or CABG is not allowed.
Main reasons for not taking part
- Planned staged PCI or CABG
- In-stent restenosis lesion
- Need for oral anticoagulation
- Major bleeding within 30 days, or hemorrhagic stroke ever, or ischemic stroke within 6 months
- Platelet count below 100,000/mm3, or current or potential pregnancy
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age >=19 years
- Diagnosis of acute coronary syndrome, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina (UA)
- Successful IVUS-guided PCI (with DES for culprit and DES or DCB for non-culprit lesions) achieving complete revascularization and meeting the mandatory procedural criteria
- Randomization within 96 hours after PCI
- Written informed consent
Who cannot take part
- Major bleeding within 30 days
- History of hemorrhagic stroke or ischemic stroke within 6 months
- Platelet count <100,000/mm3 at screening
- Planned staged PCI or CABG
- Mandatory procedural criteria not met (e.g., final TIMI flow <3, significant dissection, thrombus, or malapposition requiring correction)
- In-stent restenosis lesion
- Need for oral anticoagulation
- Contraindication to aspirin, ticagrelor, or prasugrel
- Life expectancy <1 year
- Current or potential pregnancy
- Investigator deems participation inappropriate
Where in South Korea
- Gyeongsang National University HospitalJinju, South KoreaContact: Jin-Sin Koh, MD, PhDTaking people
About the trial
What the trial wants to find out
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular ultrasound (IVUS)-guided drug-eluting stent implantation in patients with acute coronary syndrome. A total of 2,200 patients who achieve complete revascularization after IVUS-guided percutaneous coronary intervention (PCI) and meet the predefined successful IVUS-guided PCI criteria will be randomized in a 1:1 ratio to either the early single antiplatelet therapy group (Early SAPT: ticagrelor or prasugrel monotherapy) or the standard dual antiplatelet therapy group (Standard DAPT: aspirin plus ticagrelor or prasugrel). Randomization will be performed within 96 hours after completion of PCI, and clinical follow-up will be conducted at 1 month, 3 months, 6 months, and 12 months after randomization. The primary endpoints are major adverse cardiovascular events, defined as a composite of all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, and definite or probable stent thrombosis occurring up to 12 months after randomization, and clinically relevant bleeding, defined as Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding occurring up to 12 months after randomization. This study aims to determine whether early P2Y12 inhibitor monotherapy is non-inferior to standard dual antiplatelet therapy (DAPT) for ischemic events and is superior in reducing clinically relevant bleeding.
The 2 groups in the trial
- Early Single Antiplatelet Therapy GroupTreatment being tested
Patients with acute coronary syndrome who undergo successful IVUS-guided PCI with complete revascularization will be randomized within 96 hours after PCI. After randomization, aspirin will be discontinued immediately, and patients will receive potent P2Y12 inhibitor monotherapy with either prasugrel or ticagrelor.
Treatment: Early P2Y12 Inhibitor Monotherapy
- Standard Dual Antiplatelet Therapy GroupExisting treatment, for comparison
Patients with acute coronary syndrome who undergo successful IVUS-guided PCI with complete revascularization will receive standard dual antiplatelet therapy consisting of aspirin plus a potent P2Y12 inhibitor for 12 months.
Treatment: Standard Dual Antiplatelet Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Single Antiplatelet Therapy With a Potent P2Y12 Inhibitor After Intravascular Ultrasound-Guided PCI in Patients With Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial
- Plain-language title
- Stopping aspirin early after stent placement in people with acute coronary syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 November 2026